Dr. Kim is an accomplished physician-scientist with expertise in cardiovascular disease, translational medicine, and drug development. He earned his undergraduate degree in biomedical engineering from Harvard, MD and PhD degrees from UCLA, completed internal medicine residency at Brigham and Women’s Hospital, cardiology fellowship training at MGH, and clinical cardiac electrophysiology training at UCSF. He joined the UCSF faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. In 2013 he joined the Pfizer Cardiovascular and Metabolic (CVMET) Research Unit in Cambridge, MA and has served in multiple leadership roles over the past 4 years. He currently serves as VP, Clinical Research Head for CVMET, and oversees clinical research efforts for cardiometabolic diseases such as NASH, diabetes, obesity and heart failure. He has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the FDA in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. Beyond his roles at Pfizer, he also holds academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and at Harvard Medical School.
- VA Boston Healthcare System
- University of California, Los Angeles, MD
- University of California, Los Angeles, PhD
- Harvard College, AB
- Published on 4/1/2018
Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018 04 01; 4(2):119-127. PMID: 29194462.
- Published on 3/27/2017
Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 Jun; 19(6):718-727. PMID: 28345190.
- Published on 3/17/2017
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 04 20; 376(16):1517-1526. PMID: 28304227.
- Published on 6/1/2016
Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Floch CL, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]. Eur J Heart Fail. 2016 06; 18(6):727. PMID: 27324688.
- Published on 4/12/2016
Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail. 2016 May; 18(5):482-9. PMID: 27071916.
- Published on 10/30/2012
Sung RK, Kim AM, Tseng ZH, Han F, Inada K, Tedrow UB, Viswanathan MN, Badhwar N, Varosy PD, Tanel R, Olgin JE, Stephenson WG, Scheinman M. Diagnosis and ablation of multiform fascicular tachycardia. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):297-304. PMID: 23110306.
- Published on 1/26/2012
Erdemli G, Kim AM, Ju H, Springer C, Penland RC, Hoffmann PK. Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation. Front Pharmacol. 2012; 3:6. PMID: 22303294.
- Published on 10/1/2010
Yang Y, Varma N, Badhwar N, Tanel RE, Sundara S, Lee RJ, Lee BK, Tseng ZH, Marcus GM, Kim AM, Olgin JE, Scheinman MM. Prospective observations in the clinical and electrophysiological characteristics of intra-isthmus reentry. J Cardiovasc Electrophysiol. 2010 Oct; 21(10):1099-106. PMID: 20455984.
- Published on 7/9/2010
Deo M, Boyle PM, Kim AM, Vigmond EJ. Arrhythmogenesis by single ectopic beats originating in the Purkinje system. Am J Physiol Heart Circ Physiol. 2010 Oct; 299(4):H1002-11. PMID: 20622103.
- Published on 10/12/2009
Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N, Lee RJ, Tseng ZH, Lee BK, Olgin JE. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010; 7(2):149-54. PMID: 20022819.
View 10 more publications: View full profile at BUMC